Will Ford’s EV Gamble Pay Off?
As we race towards the end of 2024, a full 17 million electric vehicles are projected to be sold, which if realized will translate to a whopping 1 in 5 of all car sales.
With demand for EV’s as strong as ever and competition from Tesla and China’s BYD stiffening, what does the future hold for Ford and its EV strategy? » Read more about: Will Ford’s EV Gamble Pay Off? »
Read More
Market Commentary: Why Did Nvidia Go Up So Much?
A powerful investing lesson lies hidden in the movement of Nvidia this year. As the calendar turned to 2023, the stock was trading at $143 per share. Within fewer than two quarters, it had catapulted well above $300 per share. What could justify a 169% year-to-date return?
Read More
Market Commentary: Is This The Safest Bank In America?
In 2022, Forbes released a “Best Banks In America” list and placed one little-known bank at the top of the list. Impressively, it was the third time five years that the bank had topped the prestigious list. Yet few investors are aware of this under-the-radar bank: Home Bancshares.
At time when interest rates are rising and banks are dropping like flies,
» Read more about: Market Commentary: Is This The Safest Bank In America? »
Read More
Market Commentary: Stock You Know Well Has 38.6% Upside
Billionaires like Buffett claim the headlines but Jeffrey C Smith has grown in prominence to build over $5 billion in assets under management. Remarkably, his largest position commands a 14.7% stake in his portfolio, and he’s allocated it to a well-known stock that appears significantly undervalued: GoDaddy. What’s the bull case for his purchase?
Read More
10 Billion Reasons To Own This Recession-Proof Stock
With concerns of an impending recession looming large and Goldman Sachs pivoting away from momentum stocks to value stocks, one stock that may fit the bill is Procter & Gamble.
Although the share price has been somewhat volatile subsequent to fiscal Q4 2024 earnings results, P&G bounced back nicely to make an assault on all-time highs.
» Read more about: 10 Billion Reasons To Own This Recession-Proof Stock »
Read MoreThe Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
1 Cash Cow with Massive Upside
CVS Health (NYSE:CVS) share price declined by over 23% over the past twelve months. Hurting shareholders was the recent leadership transition from CEO Karen Lynch to David Joyner, a shift that brought uncertainty to the company’s direction as investors questioned the company’s stability while facing ongoing challenges.
» Read more about: 1 Cash Cow with Massive Upside »
Read MoreThe Daily
Should You Buy Warren Buffett's 3 Best-Performing Stocks So Far This Year?
Many investors are anxious these days, with the stock market going topsy-turvy. I doubt Warren Buffett is one of them, though. The legendary investor is worth billions more now than he was at the beginning of the year,
» Read more about: Should You Buy Warren Buffett's 3 Best-Performing Stocks So Far This Year? »